Efron Paul 4
4 · Keenova Therapeutics plc · Filed Jul 17, 2026
Research Summary
AI-generated summary of this filing
Keenova Therapeutics Director Efron Paul Receives 4,406 RSUs
What Happened
Efron Paul, a director of Keenova Therapeutics plc, was granted 4,406 restricted stock units (RSUs) on July 15, 2026. The award is a derivative grant recorded at $0.00 per unit (no cash purchase). Each RSU will convert into one ordinary share upon vesting, so the grant represents potential future issuance of 4,406 shares.
Key Details
- Transaction date: 2026-07-15; Grant type: A (Award/Grant).
- Units granted: 4,406 RSUs; reported acquisition price: $0.00 (no cash paid).
- Derivative detail: RSUs settle 1:1 into ordinary shares upon vesting (Footnote F1).
- Vesting: RSUs vest on the earlier of (i) first anniversary of grant or (ii) the Issuer’s next annual general meeting (Footnote F2).
- Shares owned after transaction: Not disclosed in the provided filing.
- Filing/Timeliness: Form 4 filed 2026-07-17 for a 2026-07-15 grant — appears timely (no late filing indicated).
- Additional remark: This Form 4 also serves as notice to the Issuer under Part V of the Companies Act 2014.
Context
RSU grants are compensation awards that convert into actual shares only when they vest; they do not represent an immediate market purchase or sale. Such awards are common for directors and officers and are primarily a compensation/retention mechanism — they should be interpreted as potential future dilution rather than an immediate insider buy or sell.
Insider Transaction Report
- Award
Restricted Stock Units
[F1][F2]2026-07-15+4,406→ 8,390 total→ Ordinary Shares (4,406 underlying)
Footnotes (2)
- [F1]Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
- [F2]The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.